Tadalafil and Acetazolamide Versus Acetazolamide in Acute Mountain Sickness Prevention
Information source: Sheba Medical Center
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pulmonary Edema; Cerebral Edema
Intervention: Tadalafil and acetazolamide (Drug); Acetazolamide (Drug)
Phase: N/A
Status: Completed
Sponsored by: Sheba Medical Center
Summary
To evaluate the additive value of tadalafil given together with Diamox (acetazolamide) in
preventing acute mountain sickness in travelers to high altitude areas.
Clinical Details
Official title: Tadalafil and Acetazolamide Versus Acetazolamide in Acute Mountain Sickness Prevention
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Primary outcome: Results will be evaluated by using the Lake Louise AMS scoring system
Detailed description:
A randomized controlled study comparing:
Tadalafil [20mg x1/day] and acetazolamide [125mg x2 day], versus Acetazolamide [125mg x2
day] alone, in trekkers to altitude > 3,000 m.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Participant in trekking to high altitude
- Agreement to sign the informed consent.
Exclusion Criteria:
- No agreement to sign informed consent.
Locations and Contacts
Tel Hashomer, Israel
Center of Geographic Medicine, Tel Hashomer, Israel
Sheba Medical Ctr., Tel hashomer, Israel
Additional Information
Starting date: January 2006
Last updated: September 7, 2012
|